Tag: percutaneous coronary intervention (PCI)

1. Revascularization guided by fractional flow reserve (FFR) was shown not to have significant benefit compared to angiography for patients with ST segment-elevated myocardial infarction. 2. The wide confidence intervals for the estimate of treatment effect were unable to conclusively interpret the study’s findings. Evidence Rating Level: 1 (Excellent) Study Rundown: Percutaneous...
1. Rate of age-related memory decline did not significantly differ when comparing individuals over the age of 65 who underwent percutaneous coronary intervention (PCI) versus coronary artery bypass grafting. 2. Coronary artery bypass grafting that involved the use of a cardiopulmonary bypass pump was associated with a greater rate of...
1. Guided selection of antiplatelet therapy reduced rates of major adverse cardiovascular event rates compared to standard therapy. 2. Guided selection strategy was beneficial for both escalation and de-escalation of standard therapy, balancing patient-dependent ischemic and bleeding risks.  Evidence Rating Level: 1 (Excellent) Study Rundown: Patients who undergo percutaneous coronary intervention (PCI)...
1. Patients without standard modifiable cardiovascular risk factors (SMuRFs) had a significantly higher all-cause mortality at 30 days after first presentation of STEMI. 2. Patients without SMuRFs were significantly less likely to receive statins, ACEIs, ARBs, or beta-blockers at discharge.  Evidence Rating Level: 2 (Good) Study Rundown: Standard modifiable cardiovascular risk factors...
1. There was no significant difference in periprocedural myonecrosis between ticagrelor and clopidogrel among patients undergoing high-risk elective PCI. 2. Ticagrelor treatment was associated with an increased rate of minor bleeding at 30 days post-operation. Evidence Rating Level: 1 (Excellent) Study Rundown: Percutaneous coronary intervention (PCI) provides a safe therapeutic option for patients with...
1. There was no significant difference in periprocedural myonecrosis between ticagrelor and clopidogrel among patients undergoing high-risk elective PCI. 2. Ticagrelor treatment was associated with an increased rate of minor bleeding at 30 days post-operation. Evidence Rating Level: 1 (Excellent) Study Rundown: Percutaneous coronary intervention (PCI) provides a safe therapeutic option for...
1. The rate of clinical events and all-cause mortality was similar in patients with drug-coated balloon therapy compared to those with drug-eluting stent therapy. 2. Treatment with drug-coated balloons yielded non-significantly decreased rates of major bleeding and probable or definite stent thrombosis.  Evidence Rating Level: 1 (Excellent) Study Rundown: Drug-coated balloons (DCBs)...
1. The revalidated SYNTAX score II 2020 was effective at predicting 10-year all-cause mortality in patients undergoing percutaneous coronary intervention (PCI) vs. coronary artery disease bypass graft (CABG). 2. The SYNTAX score II 2020 proved effective at predicting major cardiovascular events (all-cause death, non-fatal stroke, non-fatal myocardial infarction) 5-years post-procedure. Evidence...
1. Patients with severely reduced left ventricular ejection fraction with left main, left anterior descending, or multivessel disease who underwent percutaneous coronary intervention demonstrated higher rates of mortality and major adverse cardiovascular events compared to those who underwent coronary artery bypass grafting. Evidence Rating Level: 2 (Good) There is insufficient evidence in...
1. In this modern population of Canadian patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI), the rates of major adverse cardiovascular events (MACE) at 1 year follow-up were the same in groups treated with ticagrelor or clopidogrel. Ticagrelor was linked with a higher risk of...